CLORAZEPATE DIPOTASSIUM

Post-LOE

clorazepate dipotassium

PharmaIN

ANDAORALTABLET

Approved

Jun 1987

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

CLORAZEPATE DIPOTASSIUM (clorazepate dipotassium) by PharmaIN is clinical pharmacology pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1987.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. The serum half-life is about 2 days. The drug is…

Indications (3)

Worked on CLORAZEPATE DIPOTASSIUM at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.